Immunotherapy for Infectious Diseases

Active Immunization for HIV Infection 191
9. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a
live attenuated SIV vaccine with a deletion in the nef gene. Science 1992; 258:1938.
10. Deacon NJ, Tsykin A, Solomon A, et al. Genomic structure of an attenuated quasi species
of HIV-1 from a blood transfusion donor and recipients. Science 1995; 270:988.
11. Michael NL, Chang G, Louie LG, et al. The role of viral phenotype and CCR-5 gene
defects in HIV-1 transmission and disease progression. Nat Med 1997; 3:338.
12. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and
CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and
Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter
Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study.
Science 1997; 277:959.
13. Poignard P, Sabbe R, Picchio GR, et al. Neutralizing antibodies have limited effects on
the control of established HIV-1 infection in vivo. Immunity 1999; 10:431.
14. Pilgrim AK, Pantaleo G, Cohen OJ, et al. Neutralizing antibody responses to human
immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.
J Infect Dis 1997; 176:924.
15. Fouts TR, Binley JM, Trkola A, Robinson JE, Moore JP. Neutralization of the human
immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies
correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.
J Virol 1997; 71:2779.
16. Mo H, Stamatatos L, Ip JE, et al. Human immunodeficiency virus type 1 mutants that
escape neutralization by human monoclonal antibody IgG1b12. off. J Virol 1997; 71:6869.
17. Parren PW, Wang M, Trkola A, et al. Antibody neutralization-resistant primary isolates of
human immunodeficiency virus type 1. J Virol 1998; 72:10270.
18. Burton DR. A vaccine for HIV type 1: the antibody perspective. [Review] [76 refs]. Proc
Natl Acad Sci USA 1997; 94:10018.
19. Belshe RB, Graham BS, Keefer MC, et al. 1994. Neutralizing antibodies to HIV-1 in
seronegative volunteers immunized with recombinant gp120 from the MN strain of
HIV-1. NIAID AIDS Vaccine Clinical Trials Network. Jama 1994; 272:475.
20. Mascola JR, Snyder SW, Weislow OS, et al. Immunization with envelope subunit vaccine
products elicits neutralizing antibodies against laboratory-adapted but not primary isolates
of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious
Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996; 173:340.
21. Connor RI, Korber BT, Graham BS, et al. Immunological and virological analyses of persons
infected by human immunodeficiency virus type 1 while participating in trials of
recombinant gp120 subunit vaccines. J Virol 1998; 72:1552.
22. Letvin NL. Progress in the development of an HIV-1 vaccine. Science 1998; 280:1875.
23. Moore JP, Cao Y, Qing L, et al. Primary isolates of human immunodeficiency virus type
1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their
neutralization is not predicted by studies with monomeric gp120. J Virol 1995; 69:101.
24. Reitter JN, Means RE, Desrosiers RC. A role for carbohydrates in immune evasion in
AIDS. Nat Med 1998; 4:679.
25. Wyatt R, Kwong PD, Desjardins E, et al. The antigenic structure of the HIV gp120 envelope
glycoprotein. Nature 1998; 393:705.
26. Yang OO, Kalams SA, Rosenzweig M, et al. Efficient lysis of human immunodeficiency
virus type 1-infected cells by cytotoxic T lymphocytes. J Virol 1996; 70:5799.
27. Yang OO, Kalams SA, Trocha A, et al. Suppression of human immunodeficiency virus
type 1 replication by CD8� cells: evidence for HLA class I-restricted triggering of
cytolytic and noncytolytic mechanisms. J Virol 1997; 71:3120.
28. Wagner L, Yang OO, Garcia-Zepeda EA, et al. Beta-chemokines are released from
HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature 1998;
391:908.